Welcome to our dedicated page for Forward Pharma A/S news (Ticker: FWPAY), a resource for investors and traders seeking the latest updates and insights on Forward Pharma A/S stock.
Forward Pharma A/S is a biotechnology company dedicated to developing innovative immunomodulatory compounds for psoriasis and other autoimmune disorders. Their lead drug candidate, FP 187, is an orally administered small molecule that has successfully completed phase I clinical trials. Established in 2005 and headquartered in Copenhagen, Denmark, with operations in Leipzig, Germany since 2007, the company is at the forefront of research in the field of immunotherapy.
Rhea-AI Summary
Forward Pharma A/S (Forward) announced the termination of the Deposit Agreement, dated October 14, 2014, resulting in the termination of the existing ADR facility effective February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
FAQ
What is the market cap of Forward Pharma A/S (FWPAY)?
The market cap of Forward Pharma A/S (FWPAY) is approximately 7.4M.
What is Forward Pharma A/S focused on?
Forward Pharma A/S is focused on developing novel immunomodulatory compounds for the treatment of psoriasis and other autoimmune and inflammatory disorders.
What is their lead drug candidate?
Their lead drug candidate is FP 187, an oral small molecule that has successfully completed phase I clinical trials.
When was Forward Pharma A/S founded?
Forward Pharma A/S was founded in 2005.
Where is Forward Pharma A/S headquartered?
Forward Pharma A/S is headquartered in Copenhagen, Denmark, in the heart of Medicon Valley.
Where else does Forward Pharma A/S operate?
Since 2007, Forward Pharma A/S has been operating out of a subsidiary in Leipzig, Germany.
What recent announcement did Forward Pharma A/S make?
Forward Pharma A/S announced the termination of the Deposit Agreement, effective February 5, 2024.
How can investors contact Forward Pharma A/S?
Investors can reach out to Forward Pharma A/S Investor Relations at investors@forward-pharma.com.
What type of compounds does Forward Pharma A/S develop?
Forward Pharma A/S focuses on developing immunomodulatory compounds.
What phase of clinical trials has FP 187 completed?
FP 187 has successfully completed phase I clinical trials.
Where can more information about the termination of the Deposit Agreement be found?
Additional information can be found on the website of the Depositary Bank of New York Mellon.
Forward Pharma A/S